Survival, toxicity, and sequencing: navigating the new first-line standard established by FLAURA2 [0.03%]
FLAURA2研究确立了新的标准一线治疗方案：生存、毒性及 sequencinɡ 的考量
Satoshi Ikeda,Keigo Araki,Mai Kitagawa et al.
Satoshi Ikeda et al.
Air pollution, driver mutations, and survival in non-small cell lung cancer: insights from a high-altitude Hispanic cohort [0.03%]
空气污染、驱动基因突变和非小细胞肺癌患者的生存率：来自高原地区西班牙裔人群队列的启示
Mateo Tamayo,Nicolás Duque-Clavijo,Astrid Berena Herrera-López et al.
Mateo Tamayo et al.
Background: Lung cancer remains a critical global health concern, with a substantial fraction arising in never-smokers. Air pollution-including particulate matter (PM2.5, PM10), nitrogen dioxide (NO2), sulfur dioxide (SO2...
Predictors of radiation pneumonitis after postoperative radiotherapy in completely resected pathologic stage III-N2 non-small cell lung cancer: a secondary analysis of a prospective cohort [0.03%]
完全性手术切除的III期N2期非小细胞肺癌患者术后放疗后放射性肺炎的预测因素：前瞻性队列研究的二次分析
Nengyang Wang,Aihui Feng,Hongxuan Li et al.
Nengyang Wang et al.
Background: Non-small cell lung cancer (NSCLC) patients undergoing postoperative radiotherapy (PORT) after lung resection present a unique challenge due to anatomical changes and reduced baseline lung capacity. Standard d...
"Variant matters": the impact of ALK fusion subtypes on progression and response in non-small-cell lung cancer-data from clinical practice from Polish centers [0.03%]
“变异类型影响”：ALK融合亚型对非小细胞肺癌进展和反应的影响-来自波兰中心临床实践的数据
Kinga Winiarczyk,Katarzyna Seliga,Paweł Krawczyk et al.
Kinga Winiarczyk et al.
Background: For patients with advanced non-small-cell lung cancer (NSCLC) who have anaplastic lymphoma kinase (ALK) gene rearrangements, targeted therapy with ALK inhibitors (ALKi) is now regarded as the standard of care....
The IASLC grading system as a predictor for EGFR-TKI therapy in patients with EGFR-mutant lung adenocarcinoma [0.03%]
基于I期和II期临床试验结果的EGFR突变肺腺癌患者分级系统用于预测EGFR-TKI疗效的能力
Chaoqiang Deng,Molin Zhang,Fangqiu Fu et al.
Chaoqiang Deng et al.
Background: We previously validated the grading system proposed by International Association for the Study of Lung Cancer (IASLC) for invasive nonmucinous lung adenocarcinoma (LADC) for its reproducibility, prognosticatio...
Occupational physical workload and risk of lung cancer and chronic respiratory diseases: a prospective cohort study of the UK Biobank [0.03%]
基于英国生物样本库的大规模前瞻性队列研究：职业体力劳动与肺癌和慢性呼吸系统疾病风险的关系
Shuxiao Ma,Yi Liu,Zihuai Wang et al.
Shuxiao Ma et al.
Background: Occupational physical workload has been recognized as a potential, yet understudied, determinant of lung cancer and chronic respiratory diseases (CRDs). However, large-scale prospective evidence remains scarce...
TLR7 induces autophagy in non-small cell lung cancer tumor cells and influences anti-tumors responses in patients [0.03%]
toll样受体7诱导非小细胞肺癌肿瘤细胞自噬并影响患者的抗肿瘤反应
Lucas Leonardi,Solenne Marmier,Nathalie Josseaume et al.
Lucas Leonardi et al.
Background: Autophagy is a fundamental catabolic process with context-dependent roles in cancer. In non-small cell lung cancer (NSCLC), its clinical significance and therapeutic implications remain unclear. Toll-like rece...
Beyond miRNAs: exploratory profiling of PIWI-interacting RNAs and small nucleolar RNAs in non-small cell lung cancer-related malignant pleural effusions [0.03%]
超越miRNA：探索性绘制非小细胞肺癌相关恶性胸腔积液中PIWI相互作用RNA和小核仁RNA图谱
Joel Gabàs,Rui Alves,José M Porcel et al.
Joel Gabàs et al.
Background: Small RNAs in pleural fluid (PF) are increasingly being explored as potential sources of biological insight in malignant pleural effusion (MPE). While several microRNAs (miRNAs) have been explored, the presenc...
Mid-term efficacy and safety of transbronchial cryoablation for stage IA peripheral lung cancer: a retrospective analysis [0.03%]
经支气管冷冻消融治疗IA期周围型肺癌的中期疗效和安全性：回顾性分析
Rui Yang,Junxiang Chen,Fangfang Xie et al.
Rui Yang et al.
Background: Transbronchial cryoablation is an emerging treatment option for patients with early-stage lung cancer who are not candidates for surgery or who decline surgery. However, evidence regarding its efficacy and saf...
Cadonilimab induction and consolidation for unresectable stage III non-small cell lung cancer patients receiving concurrent chemoradiation: safety run-in results of a prospective, phase II trial [0.03%]
卡度尼利单抗联合同期放化疗治疗不可切除Ⅲ期非小细胞肺癌患者：一项前瞻性Ⅱ期临床研究的安全性导入结果
Jianjiao Ni,Zilu Zheng,Xi Yang et al.
Jianjiao Ni et al.
Background: Concurrent chemoradiotherapy (cCRT) followed by durvalumab consolidation remains the standard of care for unresectable stage III non-small cell lung cancer (NSCLC). However, treatment outcomes remain suboptima...